Press releases

Cameron is developing a next-generation implantable cardioverter defibrillator (ICD) for the cardiac rhythm management market.

Represents a first-of-its-kind treatment option in Canada for carotid artery disease

Companies intend to continue a pre-existing collaboration in the development of less-invasive surgical tools for the treatment of arrhythmias, particularly atrial fibrillation.

Analyst meeting on Monday, February 23 will focus on the Company's outlook for 2004 and beyond.

New 120,000 square-foot building at the Maple Grove campus will house primarily research and development laboratories and offices.